The trademark application was filed by AstraZeneca UK Limited, a corporation established under the laws of the United Kingdom of Great Britain and Northern Ireland (the "Applicant"). The application was published for oppositions on May 4, 2021, and it was registered by office on August 11, 2021 without any oppositions.
The application was filed in English (German was selected as the second language).